Eeles R, Goh C, Castro E, Bancroft E, Guy M, Al Olama AA, Easton D, Kote-Jarai Z. The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol. 2014;11:18–31.

Article  PubMed  CAS  Google Scholar 

Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun (Lond). 2021;41:1037–48.

Article  PubMed  Google Scholar 

Lokeshwar SD, Klaassen Z, Saad F. Treatment and trials in non-metastatic castration-resistant prostate cancer. Nat Rev Urol. 2021;18:433–42.

Article  PubMed  Google Scholar 

Thomsen MK, Busk M. Pre-clinical models to study human prostate Cancer. Cancers (Basel). 2023;15:4212.

Angappulige DH, Mahajan NP, Mahajan K. Epigenetic underpinnings of tumor-immune dynamics in prostate cancer immune suppression. Trends Cancer. 2024;10:369–81.

Zaalberg A, Pottendorfer E, Zwart W, Bergman AM. It takes two to Tango: the interplay between prostate Cancer and its microenvironment from an epigenetic perspective. Cancers (Basel). 2024;16:294.

Feng D, Xiong Q, Wei Q, Yang L. Cellular landscape of tumour microenvironment in prostate cancer. Immunology. 2023;168:199–202.

Article  PubMed  CAS  Google Scholar 

Kang J, La Manna F, Bonollo F, Sampson N, Alberts IL, Mingels C, Afshar-Oromieh A, Thalmann GN, Karkampouna S. Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. Cancer Lett. 2022;530:156–69.

Article  PubMed  CAS  Google Scholar 

Li MO, Wolf N, Raulet DH, Akkari L, Pittet MJ, Rodriguez PC, Kaplan RN, Munitz A, Zhang Z, Cheng S, Bhardwaj N. Innate immune cells in the tumor microenvironment. Cancer Cell. 2021;39:725–9.

Article  PubMed  CAS  Google Scholar 

Lin Q, Choyke PL, Sato N. Visualizing vasculature and its response to therapy in the tumor microenvironment. Theranostics. 2023;13:5223–46.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Helms E, Onate MK, Sherman MH. Fibroblast heterogeneity in the pancreatic Tumor Microenvironment. Cancer Discov. 2020;10:648–56.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Piperigkou Z, Karamanos NK. Dynamic interplay between miRNAs and the Extracellular Matrix influences the Tumor Microenvironment. Trends Biochem Sci. 2019;44:1076–88.

Article  PubMed  CAS  Google Scholar 

Shiao SL, Chu GC, Chung LW. Regulation of prostate cancer progression by the tumor microenvironment. Cancer Lett. 2016;380:340–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Abdul Sater H, Marte JL, Donahue RN, Walter-Rodriguez B, Heery CR, Steinberg SM, Cordes LM, Chun G, Karzai F, Bilusic M et al. Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer. J Immunother Cancer. 2020;8:e000655.

Wang M, Wisniewski CA, Xiong C, Chhoy P, Goel HL, Kumar A, Zhu LJ, Li R, St Louis PA, Ferreira LM, et al. Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer. Sci Transl Med. 2023;15:eade5855.

Article  PubMed  CAS  Google Scholar 

Zhang Z, Karthaus WR, Lee YS, Gao VR, Wu C, Russo JW, Liu M, Mota JM, Abida W, Linton E, et al. Tumor Microenvironment-Derived NRG1 promotes Antiandrogen Resistance in prostate Cancer. Cancer Cell. 2020;38:279–e296279.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Javier-DesLoges J, McKay RR, Swafford AD, Sepich-Poore GD, Knight R, Parsons JK. The microbiome and prostate cancer. Prostate Cancer Prostatic Dis. 2022;25:159–64.

Article  PubMed  Google Scholar 

Hirz T, Mei S, Sarkar H, Kfoury Y, Wu S, Verhoeven BM, Subtelny AO, Zlatev DV, Wszolek MW, Salari K, et al. Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses. Nat Commun. 2023;14:663.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gu CY, Dai B, Zhu Y, Lin GW, Wang HK, Ye DW, Qin XJ. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma. Mol Med. 2022;28:78.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gevaert T, Van Eycke YR, Vanden Broeck T, Van Poppel H, Salmon I, Rorive S, Muilwijk T, Claessens F, De Ridder D, Joniau S, Decaestecker C. The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients. PLoS ONE. 2020;15:e0244663.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Liu Z, Zhong J, Zeng J, Duan X, Lu J, Sun X, Liu Q, Liang Y, Lin Z, Zhong W, et al. Characterization of the m6A-Associated Tumor Immune Microenvironment in prostate Cancer to Aid Immunotherapy. Front Immunol. 2021;12:735170.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wu T, Wang W, Shi G, Hao M, Wang Y, Yao M, Huang Y, Du L, Zhang X, Ye D, et al. Targeting HIC1/TGF-beta axis-shaped prostate cancer microenvironment restrains its progression. Cell Death Dis. 2022;13:624.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mizuno K, Beltran H. Future directions for precision oncology in prostate cancer. Prostate. 2022;82(Suppl 1):S86–96.

PubMed  PubMed Central  CAS  Google Scholar 

Goel HL, Pursell B, Shultz LD, Greiner DL, Brekken RA, Vander Kooi CW, Mercurio AM. P-Rex1 promotes resistance to VEGF/VEGFR-Targeted therapy in prostate Cancer. Cell Rep. 2016;14:2193–208.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Powles T, Yuen KC, Gillessen S, Kadel EE 3rd, Rathkopf D, Matsubara N, Drake CG, Fizazi K, Piulats JM, Wysocki PJ, et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. 2022;28:144–53.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, McKay RR, Singh P, Pagliaro L, Dreicer R, et al. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol. 2022;23:899–909.

Article  PubMed  CAS  Google Scholar 

Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013;19:3621–30.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pereira M, Vale N. Repurposing alone and in combination of the antiviral saquinavir with 5-Fluorouracil in prostate and lung cancer cells. Int J Mol Sci. 2022;23:12240.

Sun L, Tuo Z, Chen X, Wang H, Lyu Z, Li G. Identification of cell differentiation trajectory-related gene signature to reveal the prognostic significance and immune landscape in prostate cancer based on multiomics analysis. Heliyon. 2024;10:e27628.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chen Z, Yang X, Chen Z, Li M, Wang W, Yang R, Wang Z, Ma Y, Xu Y, Ao S, et al. A new histone deacetylase inhibitor remodels the tumor microenvironment by deletion of polymorphonuclear myeloid-derived suppressor cells and sensitizes prostate cancer to immunotherapy. BMC Med. 2023;21:402.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Di Donato M, Zamagni A, Galasso G, Di Zazzo E, Giovannelli P, Barone MV, Zanoni M, Gunelli R, Costantini M, Auricchio F, et al. The androgen receptor/filamin A complex as a target in prostate cancer microenvironment. Cell Death Dis. 2021;12:127.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Y, Zhu S, Du Y, Xu F, Sun W, Xu Z, Wang X, Qian P, Zhang Q, Feng J, Xu Y. RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion. J Exp Clin Cancer Res. 2022;41:66.

Article  PubMed  PubMed Central